Valuation: C4 Therapeutics, Inc.

Market Cap 395M 354M 327M 296M 552M 37.6B 560M 3.91B 1.56B 19.67B 1.48B 1.45B 62.31B P/E 2026 *
-3.77x
P/E 2027 * -3.4x
Enterprise Value 314M 281M 260M 235M 439M 29.86B 445M 3.1B 1.24B 15.62B 1.18B 1.15B 49.48B EV / Sales 2026 *
11.9x
EV / Sales 2027 * 12.5x
Free-Float
99.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+5.76%
1 week+7.44%
Current month+1.95%
1 month+13.93%
3 months-5.43%
6 months+19.96%
Current year+77.75%
1 week 2.94
Extreme 2.94
3.53
1 month 2.59
Extreme 2.59
3.53
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
48.75
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 2020-10-01
Director of Finance/CFO 49 2023-09-17
Chief Tech/Sci/R&D Officer 56 2024-10-27
Director TitleAgeSince
Director/Board Member 74 2015-11-30
Director/Board Member 55 2020-09-13
Director/Board Member 55 2022-03-15
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Free

Founder

3,662 0.0030%
10/1/26 Free

Director

4,618 0.0038%
9/18/26 Exercice

Chief Financial Officer

9,025 0.0073%
Change 5-day change 1-year change 3-year change Capi.($)
+5.76%+7.44%+28.11%+144.24% 395M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+4.18%+28.34%+55.07% 44.75B
+2.00%-2.90%+18.37%+119.04% 41.62B
+1.34%-3.98%+225.44%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.68%-0.22%+49.75%+160.96% 38.08B
Weighted average by Cap. +3.24%-0.29%+47.54%+161.45%

Financials

2026 *2027 *
Net sales 26.4M 23.67M 21.85M 19.82M 36.93M 2.51B 37.44M 261M 104M 1.32B 99.03M 96.96M 4.17B 22.29M 19.98M 18.45M 16.73M 31.18M 2.12B 31.61M 221M 87.86M 1.11B 83.6M 81.85M 3.52B
Net income -113M -101M -93.62M -84.9M -158M -10.77B -160M -1.12B -446M -5.63B -424M -415M -17.85B -146M -131M -121M -110M -204M -13.89B -207M -1.44B -575M -7.27B -547M -536M -23.02B
Net Debt -81.29M -72.9M -67.29M -61.02M -114M -7.74B -115M -804M -320M -4.05B -305M -299M -12.83B -117M -105M -96.97M -87.94M -164M -11.15B -166M -1.16B -462M -5.84B -439M -430M -18.48B
Projected Income Statement - Annual - C4 Therapeutics, Inc.
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
26-10-28 US$3.395 +5.76% 4,105,806
26-10-27 US$3.210 +7.72% 4,119,734
26-10-26 US$2.980 -2.61% 3,179,137
26-10-23 US$3.060 -3.77% 4,741,850
26-10-22 US$3.180 +0.32% 1,692,802
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - C4 Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.395USD
Average target price
12.86USD
Spread / Average Target
+278.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - C4 Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CCCC Stock